Literature DB >> 8887387

Balloon dacryocystoplasty: an alternative treatment for obstructed tear ducts.

D Liermann1, J Berkefeld, U Fries, R W Schalnus, H Gümpel.   

Abstract

Twenty-two patients with severe epiphora due to relative (n = 13) or absolute (n = 9) stenoses of the nasolacrimal duct were treated by means of radiologically guided balloon dacryocystoplasty. The recanalization was performed with a steerable microguide wire with flexible tip, which was advanced through the lacrimal draining system and manipulated out of the nasal cavity. A 3-mm PTA balloon was then introduced from the nasal site. In 20 of 22 cases the procedure was technically successful. Dacryocystography proved a normal lumen in 9 of 20 patients and an improvement without impairment of flow in another 8 cases. Two months after dilation a clear regression of epiphora could be demonstrated in 17 of 20 patients. The procedure was complicated by the occurrence of 2 reobstructions within the first 3 months; other serious side effects were not observed.

Entities:  

Mesh:

Year:  1996        PMID: 8887387     DOI: 10.1159/000310732

Source DB:  PubMed          Journal:  Ophthalmologica        ISSN: 0030-3755            Impact factor:   3.250


  4 in total

1.  [Balloon dilatation and Stentimplantation of the nasolacrimal duct for chronic epiphora].

Authors:  U Lachmund; D Ammann-Rauch; A Forrer; M Grob; C Petralli; L Remonda; T Roeren; K Wilhelm
Journal:  Ophthalmologe       Date:  2005-04       Impact factor: 1.059

2.  Dacryocystorhinostomy: History, evolution and future directions.

Authors:  Vladimir S Yakopson; Joseph C Flanagan; Daniel Ahn; Betsy P Luo
Journal:  Saudi J Ophthalmol       Date:  2010-10-18

3.  Antegrade balloon dilatation of nasolacrimal duct obstruction in adults.

Authors:  A Kuchar; F J Steinkogler
Journal:  Br J Ophthalmol       Date:  2001-02       Impact factor: 4.638

4.  A novel technique to recanalize the nasolacrimal duct with endodiathermy bipolar probe.

Authors:  Siddharth Agrawal; Sanjiv K Gupta; Vinita Singh; Saurabh Agrawal
Journal:  Indian J Ophthalmol       Date:  2013-12       Impact factor: 1.848

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.